Metabolic characterization of primary rat hepatocytes cultivated in parallel microfluidic biochips

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3264-3276

  Legendre, Audrey ^a   Baudoin, Régis ^a   Alberto, Giulia ^a   Paullier, Patrick ^a   Naudot, Marie ^a   Bricks, Thibault ^a   Brocheton, Jessy ^b   Jacques, Sébastien ^b   Cotton, Jérôme ^c   Leclerc, Eric ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b INSTITUT COCHIN   (France)

^c Profilomic   (France)

Author keywords

Cytochrome P450; Drug delivery system; Efflux pumps; Hepatic metabolism; Hepatocytes; in vitro models; Phase II metabolism

Indexed keywords

ABC TRANSPORTER; ABCB1B PROTEIN; ABCC2 PROTEIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2C; CYTOCHROME P450 2C6; CYTOCHROME P450 2D1; CYTOCHROME P450 2D2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; GLUCURONOSYLTRANSFERASE 1A6; GLUTATHIONE TRANSFERASE A2; HEME OXYGENASE 1; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; NQO1 PROTEIN; OXYGENASE; SULFOTRANSFERASE 1A1; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL CELL; ARTICLE; BIOCHIP; CONTROLLED STUDY; ENZYME METABOLISM; LIVER CELL; MALE; MICROFLUIDICS; NONHUMAN; OXIDATIVE STRESS; PERFUSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

CYTOCHROME P450; DRUG DELIVERY SYSTEM; EFFLUX PUMPS; HEPATIC METABOLISM; HEPATOCYTES; IN VITRO MODELS; PHASE II METABOLISM;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; EQUIPMENT DESIGN; GENE EXPRESSION REGULATION; HEPATOCYTES; MALE; MICROFLUIDIC ANALYTICAL TECHNIQUES; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; XENOBIOTICS;

EID: 84881563382     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23466     Document Type: Article

References (51)

1. Huh D, Hamilton GA, Ingber DE. 2012. From 3D cell culture to organs-on-chips. Trends Cell Biol 21(12):745-754.
2. Toh YC, Lim TC, Tai D, Xiao G, van Noort D, Yu H. 2009. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 9(14):2026-2035.
3. van Midwoud PM, Groothuis GM, Merema MT, Verpoorte E. 2010. Microfluidic biochip for the perifusion of precision-cut rat liver slices for metabolism and toxicology studies. Biotechnol Bioeng 105(1):184-194.
4. Sivaraman A, Leach JK, Townsend S, Iida T, Hogan BJ, Stolz DB, Fry R, Samson LD, Tannenbaum SR, Griffith LG. 2005. A microscale in vitro physiological model of the liver: Predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 6(6):569-591.
5. Chao P, Maguire T, Novik E, Cheng KC, Yarmush ML. 2009. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol 78(6):625-632.
6. Zhang SF, Tong WH, Zheng BX, Susanto TAK, Xia L, Zhang C, Ananthanarayanan A, Tuo XY, Sakban RB, Jia RR, Iliescu C, Chai KH, McMillian M, Shen SL, Leo H, Yu H. 2011. A robust high-throughput sandwich cell-based drug screening platform. Biomaterials 32(4):1229-1241.
7. Prot JM, Leclerc E. 2012. The current status of alternatives to animal testing and predictive toxicology methods using liver microfluidic biochips. Ann Biomed Eng 40(6):1228-1243.
8. Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. 2010. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 79(7):1036-1044.
9. Prot JM, Videau O, Brochot C, Legallais C, Benech H, Leclerc E. 2011. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. Int J Pharm 408(1-2):67-75.
10. Prot JM, Aninat C, Griscom L, Razan F, Brochot C, Guillouzo CG, Legallais C, Corlu A, Leclerc E. 2011. Improvement of HepG2/C3a cell functions in a microfluidic biochip. Biotechnol Bioeng 108(7):1704-1715.
11. Powers MJ, Janigian DM, Wack KE, Baker CS, Stolz DB, Griffith LG. 2002. Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng 8(3):499-513.
12. Leclerc E, Sakai Y, Fujii T. 2004. Perfusion culture of fetal human hepatocytes in microfluidic environments. Biochem Eng J 20(2-3):143-148.
13. Cheng S, Prot J-M, Leclerc E, Bois FY. 2012. Zonation related function and ubiquitination regulation in human hepatocellular carcinoma cells in dynamic vs. static culture conditions. BMC Genomics 13(1):54.
14. Park J, Berthiaume F, Toner M, Yarmush ML, Tilles AW. 2005. Microfabricated grooved substrates as platforms for bioartificial liver reactors. Biotechnol Bioeng 90(5):632-644.
15. Tilles AW, Baskaran H, Roy P, Yarmush ML, Toner M. 2001. Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor. Biotechnol Bioeng 73(5):379-389.
16. Sung JH, Kam C, Shuler ML. 2010. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10(4):446-455.
17. Shintu L, Baudoin R, Navratil V, Prot JM, Pontoizeau C, Defernez M, Blaise BJ, Domange C, Pery AR, Toulhoat P, Legallais C, Brochot C, Leclerc E, Dumas ME. 2012. Metabolomics-on-a-chip and predictive systems toxicology in microfluidic bioartificial organs. Anal Chem 84(4):1840-1848.
18. Prot JM, Bunescu A, Elena-Herrmann B, Aninat C, Snouber LC, Griscom L, Razan F, Bois FY, Legallais C, Brochot C, Corlu A, Dumas ME, Leclerc E. 2012. Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: Application to acetaminophen injury. Toxicol Appl Pharmacol 259(3):270-280.
19. Domansky K, Inman W, Serdy J, Dash A, Lim MH, Griffith LG. 2010. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 10(1):51-58.
20. Baudoin R, Alberto G, Legallais C, Leclerc E. 2012. Parallelized microfluidic biochips in multi well plate applied to liver tissue engineering. Sensors Actuators B 173:919-926.
21. Baudoin R, Corlu A, Griscom L, Legallais C, Leclerc E. 2007. Trends in the development of microfluidic cell biochips for in vitro hepatotoxicity. Toxicol In Vitro 21(4):535-544.
22. Mathijs K, Kienhuis AS, Brauers KJ, Jennen DG, Lahoz A, Kleinjans JC, van Delft JH. 2009. Assessing the metabolic competence of sandwich-cultured mouse primary hepatocytes. Drug Metab Dispos 37(6):1305-1311.
23. Guillouzo A, Morel F, Langouët S, Maheo K, Rissel M. 1997. Use of hepatocyte cultures for the study of hepatotoxic compounds. J Hepatol 26(Suppl. 2):73-80.
24. Guillouzo A. 1998. Liver cell models in in vitro toxicology. Environ Health Perspect 106:511-532.
25. Baudoin R, Griscom L, Prot JM, Legallais C, Leclerc E. 2011. Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor. Biochem Eng J 53(2):172-181.
26. Baudoin R, Prot JM, Nicolas G, Brocheton J, Brochot C, Legallais C, Benech E, Leclerc E. 2012. Evaluation of seven drug metabolisms and clearances by cryopreserved Human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica 43(2):140-152.
27. Seglen PO. 1973. Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. Exp Cell Res 82(2):391-398.
28. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45.
29. Tanaka N, Miyasho T, Shinkyo R, Sakaki T, Yokota H. 2006. cDNA cloning and characterization of feline CYP1A1 and CYP1A2. Life Sci 79(26):2463-2473.
30. Duffel MW, Chen G, Sharma V. 1998. Studies on an affinity label for the sulfuryl acceptor binding site in an aryl sulfotransferase. Chem Biol Interact 109(1-3):81-92.
31. Kot M, Daniel WA. 2007. Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep 59(3):296-305.
32. Jorritsma U, Schrader E, Klaunick G, Kapitulnik J, Hirsch-Ernst KI, Kahl GF, Foth H. 2000. Monitoring of cytochrome P-450 1A activity by determination of the urinary pattern of caffeine metabolites in Wistar and hyperbilirubinemic Gunn rats. Toxicology 144(1-3):229-236.
33. Hoen PA, Bijsterbosch MK, van Berkel TJ, Vermeulen NP, Commandeur JN. 2001. Midazolam is a phenobarbital-like cytochrome p450 inducer in rats. J Pharmacol Exp Ther 299(3):921-927.
34. Paine AJ, Andreakos E. 2004. Activation of signalling pathways during hepatocyte isolation: Relevance to toxicology in vitro. Toxicol In Vitro 18(2):187-193.
35. Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, Suter L. 2003. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: Possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 73(2):386-402.
36. Schrem H, Klempnauer J, Borlak J. 2002. Liver-enriched transcription factors in liver function and development. Part I: The hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol Rev 54(1):129-158.
37. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. 2002. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62(3):638-646.
38. Allen JW, Khetani SR, Bhatia SN. 2005. In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol Sci 84(1):110-119.
39. Tuschl G, Hrach J, Walter Y, Hewitt PG, Mueller SO. 2009. Serum-free collagen sandwich cultures of adult rat hepatocytes maintain liver-like properties long term: A valuable model for in vitro toxicity and drug-drug interaction studies. Chem Biol Interact 181(1):124-137.
40. Fardel O, Lecureur V, Guillouzo A. 1993. Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Lett 327(2):189-193.
41. Tuschl G, Mueller SO. 2006. Effects of cell culture conditions on primary rat hepatocytes-cell morphology and differential gene expression. Toxicology 218(2-3):205-215.
42. Barth CA, Schwarz LR. 1982. Transcellular transport of fluorescein in hepatocyte monolayers: Evidence for functional polarity of cells in culture. Proc Natl Acad Sci USA 79(16):4985-4987.
43. Kern A, Bader A, Pichlmayr R, Sewing KF. 1997. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol 54(7):761-772.
44. Kienhuis AS, Wortelboer HM, Maas WJ, van Herwijnen M, Kleinjans JCS, van Delft JHM, Stierum RH. 2007. A sandwich-cultured rat hepatocyte system with increased metabolic competence evaluated by gene expression profiling. Toxicol in Vitro 21(5):892-901.
45. Gerhold D, Lu M, Xu J, Austin C, Caskey CT, Rushmore T. 2001. Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol Genomics 5(4):161-170.
46. Kondraganti SR, Jiang W, Jaiswal AK, Moorthy B. 2008. Persistent induction of hepatic and pulmonary phase II enzymes by 3-methylcholanthrene in rats. Toxicol Sci 102(2):337-344.
47. Richert L, Binda D, Hamilton G, Viollon-Abadie C, Alexandre E, Bigot-Lasserre D, Bars R, Coassolo P, LeCluyse E. 2002. Evaluation of the effect of culture configuration on morphology, survival time, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicol In Vitro 16(1):89-99.
48. Lin JH. 2006. CYP induction-mediated drug interactions: In vitro assessment and clinical implications. Pharm Res 23(6):1089-1116.
49. Lu C, Li AP. 2001. Species comparison in P450 induction: Effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 134(3):271-281.
50. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. 1996. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93(9):4001-4005.
51. Higashikawa F, Murakami T, Kaneda T, Kato A, Takano M. 1999. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol 51(1):67-72.